Heart failure occurs when a patient has a left ventricular systolic disorder or dysfunction, resulting in an insufficient supply of oxygen and blood to the entire body. The application of valsartan and sacubitril drugs (entresto) in patients with chronic heart disorder or failure assists in minimizing the risks of hospitalization during the worst instance of heart failure, subsequently reducing death risks resulting from chronic heart failure ( Hyzy & McSparron, 2020 ). Sacubitril acts as a medicine for blood pressure in patients. Active metabolism of sacubitril inhibits neprilysin, the neutral endopeptidase that stimulates the production and release of C-type natriuretic peptide (CNP), brain natriuretic peptide (BNP), and arterial natriuretic peptide (ANP). During a patient’s ventral and arterial stress or disorder, the release of BNP and ANP activate the receptors resulting in vasodilation of the blood vessels to reduce hypertension by minimizing sodium levels.
Normal body condition promotes digestion vasoconstriction hormones like angiotensin ii in the body. Neprilysin inhibition results in minimized breakdown and promotes endogenous natriuretic peptides concentration leading to high levels of angiotensin ii in the body ( Baliga & Samal, 2018 ). Collectively, valsartan and sacubitril drugs prevent the production of angiotensin ii from the receptor, preventing vasoconstrictive consequences in a patient’s body. The drugs decrease blood pressure and vascular resistance in patients with chronic heart failure. Consequently, valsartan and sacubitril drugs decrease ejection friction and minimize cardiovascular activities in patients experiencing chronic heart disorders or failure.
Delegate your assignment to our experts and they will do the rest.
Though physicians administer valsartan and sacubitril drugs to increase the survival chance of patients, the medicines may present harmful effects on pregnant women. The drugs cause dysfunction of kidneys in unborn children, causing death ultimately. Using valsartan and sacubitril drugs results in a high concentration of potassium levels (hyperkalemia) in a patient’s body. However, the use of valsartan and sacubitril drugs reduces the risk of hospitalization. Additionally, the drugs improve survival rates of patients with chronic heart failures promoting reduced mortality rates resulting from heart failure.
References
Baliga, R. R., & Samal, U. C. (2018). Recent Advances in Management of Heart Failure, An Issue of Heart Failure Clinics . Elsevier Health Sciences.
Hyzy, R. C., & Mcsparron, J. (Eds.). (2020). Evidence-Based Critical Care: A Case Study Approach . Springer Nature.
